CellSearch for prostate cancer
This article was originally published in The Gray Sheet
Executive Summary
FDA clears metastatic prostate cancer indication for Johnson & Johnson/Veridex's CellSearch circulating tumor cell test system, Veridex announces Feb. 27. The clearance was based on a 65-center, 231-patient study which showed that circulating tumor cells are a strong independent predictor of progression-free survival and overall survival. CellSearch is already cleared to aid in monitoring metastatic breast and colorectal cancers (1"The Gray Sheet" Nov. 26, 2007, In Brief)